Burton-on-Trent, UK – 20 June 2014 – Clinigen Group (AIM: CLIN), the specialty global pharmaceutical company, has announced that CEO Peter George won the Chief Executive of the Year Award at last night’s 2014 European Mediscience Awards.
The awards ceremony held at the Hotel InterContinental in London is the largest annual gathering of private and publically quoted healthcare, biotech and life science companies in Europe. The awards celebrate the standout technologies, personalities and companies in the mediscience sector.
The judges named Peter George Chief Executive Officer of the Year based on his considerable achievements at the helm of the Clinigen Group since 2010 which include leading Clinigen through a successful listing on London Stock Exchange’s AIM in September 2012, the first in this sector for almost five years, and growing the Group significantly in only 5 years.
Ian Renstall, Chairman of the judging panel said, “Every member of the shortlist for this award is an inspirational leader, but for the panel, Peter stood out as the driving force behind Clinigen’s meteoric rise. His energy, drive and commitment to creating a rare community culture in which all members of the Group hold shares, sharing in its success, is striking.”
Peter George said, “I am incredibly proud to receive this award, especially in view of the caliber of those shortlisted alongside me. Although my name is on the award, it is a tribute to the hard work and dedication of everyone at Clinigen who has helped build the Group into a leading global provider in the specialty pharma sector. Without them, we could not have got to where we are today.”
Other members of the shortlist included Edwin Moses of Ablynx NV, Simon Mornoney of MorphoSys AG and Justin Gover of GW Pharmaceuticals plc.
About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group, dedicated to delivering ‘the right drug, to the right patient at the right time’, has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen SP focuses on acquiring and in licensing specialist, hospital only medicines worldwide and commercializing them within niche markets. Clinigen CTS sources commercial medical products for use in clinical studies only, including comparator drugs, adjuvant drugs and rescue therapies. Clinigen GAP specializes in the consultancy, development, management and implementation of programs providing access for patients and their clinicians to drugs not available in their markets. For more information, please visit www.clinigengroup.com.
Issued for and on behalf of Clinigen.
To contact the Evaluate team at Instinctif Partners, email firstname.lastname@example.org
Melanie Toyne-SewellManaging Partner